Exagen Inc (XGN)

04:10 AM

XGN PE Ratio & Valuation, Is XGN Overvalued - Intellectia AI

04:10 AM

Apr 03, 2026

XGN Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 03, 2026

Mar 31, 2026

Exagen (XGN) Price Target Increased by 12.20% to 13.41 - MSN

Mar 31, 2026

Mar 30, 2026

Exagen Inc. (NASDAQ:XGN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Mar 30, 2026

Mar 29, 2026

CEO Change: Is Exagen Inc benefiting from innovation trendsMarket Growth Review & Reliable Entry Point Trade Alerts - baoquankhu1.vn

Mar 29, 2026

Mar 27, 2026

Exagen (XGN) price target decreased by 21.78% to 10.03 - MSN

Mar 27, 2026

Mar 27, 2026

How Analyst Resets Are Reshaping The Exagen (XGN) Investment Story - Yahoo Finance

Mar 27, 2026

Mar 25, 2026

Exagen Inc stock gains spotlight ahead of Maryland MedTech Summit 2026 amid diagnostic innovation pu - AD HOC NEWS

Mar 25, 2026

Mar 22, 2026

Stop Loss: Is Exagen Incs growth already priced inGap Up & High Accuracy Trade Alerts - baoquankhu1.vn

Mar 22, 2026

Mar 16, 2026

Exagen (XGN) director lists 7,500 restricted stock units in Form 3 - Stock Titan

Mar 16, 2026

Mar 16, 2026

Exagen Inc. (NASDAQ:XGN) Short Interest Update - Defense World

Mar 16, 2026

Mar 16, 2026

Exagen (XGN) CFO receives option, RSU grants and ESPP share purchase - Stock Titan

Mar 16, 2026

Mar 16, 2026

Exagen (XGN) CEO John Aballi awarded new RSUs and options - Stock Titan

Mar 16, 2026

Mar 16, 2026

Exagen prices public offering of common stock - MSN

Mar 16, 2026

Mar 15, 2026

Exagen Inc Stock (ISIN: US30063K1051) Faces Headwinds After 2025 Revenue Beat - AD HOC NEWS

Mar 15, 2026

Mar 14, 2026

Exagen Inc Stock (ISIN: US30063K1051) Faces Headwinds After 2025 Revenue Beat and Cautious 2026 Outl - AD HOC NEWS

Mar 14, 2026

Mar 14, 2026

Exagen (NASDAQ:XGN) Downgraded by Wall Street Zen to Sell - MarketBeat

Mar 14, 2026

Mar 13, 2026

Exagen Q4 Earnings Call Highlights - Defense World

Mar 13, 2026

Mar 11, 2026

Exagen stock price target lowered to $10 by Canaccord on margin outlook - Investing.com UK

Mar 11, 2026

Mar 11, 2026

KeyBanc cuts Exagen stock price target on pricing headwinds - Investing.com Nigeria

Mar 11, 2026

Mar 11, 2026

Exagen (XGN): Canaccord Genuity Lowers Price Target to $10.00 | - GuruFocus

Mar 11, 2026

Mar 11, 2026

Canaccord Genuity Group Issues Pessimistic Forecast for Exagen (NASDAQ:XGN) Stock Price - MarketBeat

Mar 11, 2026

Mar 11, 2026

Exagen Inc. 2025 Annual Report: Innovative AVISE® Autoimmune Disease Testing, Business Strategy, Pipeline, and Intellectual Property Overview - Minichart

Mar 11, 2026

Mar 11, 2026

Analyst John Wilkin Lowers Price Target for Exagen (XGN) | XGN S - GuruFocus

Mar 11, 2026

Mar 11, 2026

KeyBanc cuts Exagen stock price target on pricing headwinds By Investing.com - Investing.com India

Mar 11, 2026

Mar 11, 2026

Exagen (NASDAQ:XGN) Price Target Cut to $10.00 by Analysts at Craig Hallum - MarketBeat

Mar 11, 2026

Mar 11, 2026

XGN: Keybanc Lowers Price Target to $10, Maintains Overweight Ra - GuruFocus

Mar 11, 2026

Mar 11, 2026

KeyCorp Issues Pessimistic Forecast for Exagen (NASDAQ:XGN) Stock Price - MarketBeat

Mar 11, 2026

Mar 11, 2026

Exagen Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:XGN) 2026-03-11 - Seeking Alpha

Mar 11, 2026

Mar 11, 2026

Exagen stock price target lowered to $10 by Canaccord on margin outlook By Investing.com - Investing.com Canada

Mar 11, 2026

Mar 11, 2026

Exagen outlines $70M–$73M 2026 revenue target while expanding sales force and innovation cadence - MSN

Mar 11, 2026

Mar 11, 2026

William Blair Maintains Outperform on Exagen Inc. (XGN) March 2026 - Meyka

Mar 11, 2026

Mar 10, 2026

BTIG cuts Exagen stock price target to $9 on lower revenue outlook By Investing.com - Investing.com India

Mar 10, 2026

Mar 10, 2026

BTIG cuts Exagen stock price target to $9 on lower revenue outlook - Investing.com India

Mar 10, 2026

Mar 10, 2026

Exagen (XGN) Rating Maintained by BTIG, Price Target Lowered to $9.00 | XGN Stock News - GuruFocus

Mar 10, 2026

Mar 10, 2026

Exagen (NASDAQ:XGN) Price Target Lowered to $9.00 at BTIG Research - MarketBeat

Mar 10, 2026

Mar 10, 2026

Exagen Inc (XGN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Investments By GuruFocus - Investing.com Canada

Mar 10, 2026

Mar 10, 2026

Exagen Inc (XGN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Investments - GuruFocus

Mar 10, 2026

Mar 10, 2026

4 Analysts Have This To Say About Exagen - Benzinga

Mar 10, 2026

Mar 10, 2026

Exagen stock maintains Outperform rating at William Blair By Investing.com - Investing.com India

Mar 10, 2026

Mar 10, 2026

Exagen stock maintains Outperform rating at William Blair - Investing.com Australia

Mar 10, 2026

Mar 10, 2026

Exagen Q4 2025 Earnings Call Transcript - MarketBeat

Mar 10, 2026

Mar 10, 2026

XGN: FY 2025 revenue rose 20% with improved margins and expanded AVISE diagnostics platform - TradingView

Mar 10, 2026

Mar 10, 2026

Earnings call transcript: Exagen Inc. misses Q4 2025 earnings expectations - Investing.com India

Mar 10, 2026

Mar 10, 2026

Exagen Inc. Reports Strong Q4 and Full-Year 2025 Financial Results – Earnings Press Release March 2026 - Minichart

Mar 10, 2026

Mar 10, 2026

Exagen (XGN) Achieves Record Q4 Revenue, Driven by Test Volume G - GuruFocus

Mar 10, 2026

Mar 10, 2026

XGN Forecasts Significant Revenue Growth by 2026 - GuruFocus

Mar 10, 2026

Mar 10, 2026

Exagen Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com

Mar 10, 2026

Mar 10, 2026

Earnings call transcript: Exagen Inc. misses Q4 2025 earnings expectations By Investing.com - Investing.com South Africa

Mar 10, 2026